nach oben

Metabolic Brain Disease

Erschienen in:

04.05.2019 | Original Article

Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats

verfasst von: Sadaf Naeem, Rahila Najam, Saira Saeed Khan, Talat Mirza, Bushra Sikandar

Erschienen in: Metabolic Brain Disease | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Neuroinflammation plays a key role in progressive degeneration of dopaminergic cells. Upregulation of prostaglandins and free radicals formation are involved in the mechanisms of cell death in Parkinson’s disease (PD). The present study aimed to investigate the neuroprotective effect of diclofenac against chlorpromazine (CPZ) induced catalepsy and motor impairment in mice. Adult Wistar rats treated with CPZ (3 mg/kg/day, IP) were orally dosed with diclofenac and L-dopa/carbidopa for 21 days. Catalepsy was measured after 21 days of dosing by using standard bar test at 30, 60, 90, 120 and 180 min then motor performances were assessed via open field test and wire hanging test. Histopathological investigation and determination of dopamine (DA) and 3,4-Dihydroxyphenylacetic acid (DOPAC) levels of rat’s brain was also carried out. We found that CPZ treated group exhibited reduced motor impairment after 21 days of treatment in open field and wire hanging test (P < 0.01) as compared to control group. The cataleptic scores of CPZ treated rats were also significantly increased (P < 0.01) after 21 days of chronic dosing, however diclofenac treated groups showed significant reduction in cataleptic scores with improved motor performances. Histopathology of CPZ treated rats showed marked degeneration with architecture distortion in the mid brain region. Dopaminergic degeneration is confirmed by neurochemical results that showed reduced amount of dopamine and DOPAC levels in mid brain. Moreover, histopathological slides of diclofenac treated rats showed improved architecture with reduced gliosis of mid brain region as well as improved dopamine and DOPAC levels were achieved after 21 days dosing of diclofenac. Taken together, the present work provide an evidence that diclofenac ameliorated behavioral performances by mediating neuroprotection against CPZ induced PD via preventing dopaminergic neuronal cell death.

Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33:430.e1–430.e3

Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3(6):1949–1964PubMed

Al-Amin MM, Uddin MM, Rahman MM, Reza HM, Rana MS (2013) Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture. Inflammopharmacology 21(6):421–425PubMed

Asanuma M, Miyazaki I, Kohno M, Ogawa N (2001) Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 76:1895–1904PubMed

Bendlin BB, Newman LM, Ries ML, Puglielli L, Carlsson CM, Sager MA, Johnson SC (2010) NSAIDs may protect against age-related brain atrophy. Front Aging Neurosci 2:35PubMed

Bigoniya P, Rana AC (2005) Psychopharmacological profile of hydro-alcoholic extract of euphorbia Neriifolia leaves in mice and rats. Indian J Exp Biol 43:859–862PubMed

Bishnoi M, Chopra K, Kulkarni SK (2006) Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 552(1–3):55–66PubMed

Bonetto A, Andersson DC, Waning DL (2015) Assessment of muscle mass and strength in mice. Bonekey Rep 4:732PubMedPubMedCentral

Cairo TA, Woodward TS, Ngan ET (2006) (2006). Decreased encoding efficiency in schizophrenia. Biol Psychiatry 59:740–746PubMed

Carta AR, Pisanu A (2013) Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotox Res 23(2):112–123PubMed

Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 289:201–20410PubMed

Chen T, Koga K, Li XY, Zhuo M (2010) Spinal microglial motility is independent of neuronal activity and plasticity in adult mice. Mol Pain 6:19PubMedPubMedCentral

Choi SH, Aid S, Bosetti F (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 30:174–181PubMedPubMedCentral

Choi S-H, Aid S, Caracciolo L, Sakura Minami S, Niikura T, Matsuoka Y, Turner RS, Mattson MP, Bosetti F (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem 124(1):59–68PubMed

Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558–567PubMed

Conner EM, Grisham MB (1996) Inflammation, free radicals an antioxidants. Nutrition 12:274–277

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909PubMed

De La Garza R, Asnis GM (2003). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus Brain Res 4;977(1):70-9

De La Garza R, Fabrizio KR, Radoi GE, Vlad T, Asnis GM (2004) (2004). The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release. Behav Brain Res 149(1):77–85

De La Garza R, Asnis GM, Fabrizio KR, Pedrosa E (2005) Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. Psychopharmacology (Berl) 179(2):356–365

Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012, Article ID 645460:13

Díaz-González F, Sánchez-Madrid F (2015) NSAIDs: learning new tricks from old drugs. Eur J Immunol 45(3):679–686PubMedPubMedCentral

Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T (2011) Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ 342:d198PubMedPubMedCentral

Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349–372PubMed

Fahn S, Przedborski S (2000) Parkinsonism. In: Rowland LP (ed) Parkinsonism in Merritt’s neurology. Lippincott, Williams & Wilkins, New York, pp 679–693

Feng Z, Li D, Fung PCW, Pei Z, Ramsden DB, Ho S (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. NeuroReport 14(15):1927–1929PubMed

Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259–272PubMed

Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140(6):918–934PubMedPubMedCentral

Griffin WS (2006) (2006). Inflammation and neurodegenerative diseases. Am J Clin Nutr 83:470–474

Guldberg HC, Yates CM (1969) Effects of chlorpromazine on the metabolism of catecholamines in dog brain. Br J Pharmacol 36(3):535–548PubMed

Hassanein NM, Hasan WA, Hamed MR (2004) (2004). Effects of diclofenac, piroxicam and alpha-tocopherol on monoaminelymphopoietic interfacing in mice. Arzneimittelforschung. 54(12):847–856PubMed

Hernandes MS, Britto LRG (2012) NADPH Oxidase and Neurodegeneration. Curr Neuropharmacol 10(4):321–327PubMed

Homykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2–S9

Hoozemans JJ, O'Banion MK (2005) The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4:307–315PubMed

Jaturapatporn D, Isaac MG, Mc-Cleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2:CD006378

Kaplan AA, Yurt KK, Deniz OG, Altun G (2017) Peripheral nerve and diclofenac sodium: molecular and clinical approaches. J Chem Neuroanat 87:2–11PubMed

Karch AM (2009). Focus on nursing pharmacology, 5thed. Philadelphia: Lippincott Williams & Wilkins; publishing CO, New York, pp. 548–551

Khatoon H, Najam R, Mirza T, Sikandar B (2016) Beneficial anti-parkinson effects of camel milk in Chlorpromazine- induced animal model: Behavioural and histopathological study. Pak J Pharm Sci 29(5):1525–1529PubMed

Klockgether T (2004) Parkinson’s disease:clinical aspects. Cell Tissue Res 318:115–120PubMed

Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesołowska A, Newman-Tancredi A (2014) Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. NaunynSchmiedeberg’s. Arch Pharmacol 387(6):545–557

Krause DL, Müller N (2010) Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis 2010:732806PubMedPubMedCentral

Kulkarni SK (2007). Handbook of experimental pharmacology: 3 ^rd revised ed. New Delhi: VallabhPrakashan; p. 135-7

L’ Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B (2010) Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 9:349–372

Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPAR gamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5:481–489PubMedPubMedCentral

Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46(4):598–605PubMed

Makunts T, Cohen IV, Lee KC, Abagyan R (2018) Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PLoS One 13(4):e0195521PubMedPubMedCentral

Marsden CD, Calne DB (1994) Recent development in parkinson's disease. Florham Park, Macmillan; Health Care Information, pp 153–164

Milusheva E, Baranyi M, Kittel A, Fekete A, Zelles T, Vizi ES, Sperlágh B (2008) Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment. J Neurochem 105(2):360–368PubMedPubMedCentral

Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a009381PubMedPubMedCentral

Naeem S, Ikram R, Khan SS, Rao SS (2017) NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Pak J Pharm Sci 30(3):801–808PubMed

Nair V, Arjuman A, Dorababu P, Gopalakrishna HN, Rao UC, Mohan L (2007) Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. Indian J Med Res 126:480–484PubMed

Ng F, Berk M, Dean O, Bush AI (2008) 2008. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11(6):851–876PubMed

Parepally JM, Mandula H, Smith QR (2006) Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 23:873–881PubMed

Parikh V, Khan MM, Mahadik SP (2003) Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37:43–51PubMed

Pires JG, Bonikovski V, Futuro-Neto HA (2005) Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 38(12):1867–1872 EpubPubMed

Pizza V, Agresta A, D'Acunto CW, Festa M, Capasso A (2011) Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 10(5):621–634PubMed

Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–145PubMed

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66–71PubMed

Riaz B, Ikram R, Sikandar B (2018 Mar) 2018. Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. Pak J Pharm Sci 31(2):393–397PubMed

Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966(2):245–252PubMed

Sandhu K, Rana A (2013). Evaluation of antiparkinson’s activity of Nigella Sativa seeds in chlorpromazine induced experimental animal model . Academic Sciences: Aug 201, Vol 5, Suppl 3, 0975-1491

Sestakova N, Puzserova A, Kluknavsky M, Bernatova I (2013) Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide. Interdiscip Toxicol 6(3):126–135PubMedPubMedCentral

Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (2000) Action of adenosine A2A receptor antagonist KW-6002 on drug induced catalepsy and hypokinesia caused by reserpine. Psychopharmacology 1324

Swiatkiewicz M, Zaremba M, Joniec I, Cztonkowski A, Kurkowska-Jastrzebska I (2013) Potential neuroprotective effect of ibuprofen, insight from the mice model of Parkinson disease. Pharmacol Rep 65:1227–1236 Issue 1734-1140PubMed

Taepavarapruk P, Floresco SB, Phillips AG (2000) Hyperloco-motion and increased dopamine efflux in the rat nucleus accumbens evoked by electrical stimulation of the ventral subiculum: role of ionotropic glutamate and dopamineD₁ receptors. Psychopharmacology (Berlin) 151:242–251

Takahashi E, Niimi K, Itakura C (2009) Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice. Brain Res 1279:50–57PubMed

Takween S, Ahmed SP, Haider S, Haleem DJ (1998) Effect of chlorpromazine on brain biogenic amines in normal and hyperglycemic state. Pak J Pharm Sci 11(2):23–29PubMed

Tansey MG, Goldberg MS (2009) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–518PubMedPubMedCentral

Terry AV, Warner SE, Vandenhuerk L, Pillai A, Mahadik SP, Zhang G, Bartlett MG (2008) Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156(4):1005–1016PubMedPubMedCentral

Terzi M, Altun G, Şen S, Kocaman A, Kaplan AA, Yurt KK, Kaplan S (2018) The use of non-steroidal anti-inflammatory drugs in neurological diseases. J Chem Neuroanat 87:12–24PubMed

Ton TG, Heckbert SR, Longstreth WT et al (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 21:964–969PubMed

Townsend KP, Pratico D (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:1592–1601PubMed

Wakade CG, Mahadik SP, Waller JL, Chiu FC (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69:72–79PubMed

Walker D, Lue L-F (2007) Anti-inflammatory and immune therapy for Alzheimer’s disease: current status and future directions. Curr Neuropharmacol 5(4):232–243PubMed

Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 4:19PubMed

Whitton PS (2007) Inflammation as a causative factor in the etiology of Parkinson's disease. Br J Pharmacol 150(8):963–976PubMed

Yamada T, Kawamata T, Walker DG, McGeer PL (1992) Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 84(2):157–162PubMed

Zhang W, Wang T, Pei Z et al (2005) Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19(6):533–542PubMed

Titel: Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats
verfasst von: Sadaf Naeem
Rahila Najam
Saira Saeed Khan
Talat Mirza
Bushra Sikandar
Publikationsdatum: 04.05.2019
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 4/2019
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-019-00416-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Melatonin-pretreated adipose-derived mesenchymal stem cells efficeintly improved learning, memory, and cognition in an animal model of Alzheimer's disease

Omega-3 fatty acid supplementation can prevent changes in mitochondrial energy metabolism and oxidative stress caused by chronic administration of L-tyrosine in the brain of rats

Neuroprotective effects of lovastatin in the pilocarpine rat model of epilepsy according to the expression of neurotrophic factors

Magnesium sulfate protects blood–brain barrier integrity and reduces brain edema after acute ischemic stroke in rats

Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review

Association of long noncoding RNA H19 polymorphisms with the susceptibility and clinical features of ischemic stroke in southern Chinese Han population

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie